小分子同时减轻帕金森病动物模型中的帕金森症状与左旋多巴诱导的运动障碍
该研究通过分析不同剂量左旋多巴处理小鼠纹状体的转录组数据,区分了左旋多巴抗帕金森症状与致运动障碍的基因表达特征,并据此识别出蛋白激酶A II型正性变构调节剂SB-0107。在MPTP损伤猕猴模型中,SB-0107增强左旋多巴疗效并减少运动障碍,其氘代类似物SB-0110进一步改善了药代动力学和药理效应。
要点
- 左旋多巴的抗帕金森作用与致运动障碍作用具有不同的纹状体基因表达特征。
- SB-0107在MPTP损伤猕猴中增强左旋多巴疗效并减少运动障碍。
- 氘代类似物SB-0110改善了药代动力学和药理效应。
核心结论
- SB-0107作为蛋白激酶A II型正性变构调节剂,在帕金森病动物模型中可同时增强左旋多巴的抗帕金森疗效并减少运动障碍。
- 氘代类似物SB-0110改善了药代动力学和药理效应,支持其作为左旋多巴辅助治疗的进一步开发。
研究设计与样本
- 分析不同剂量左旋多巴处理小鼠纹状体的转录组数据,识别与抗帕金森作用和运动障碍相关的基因表达特征。
- 将上述特征与大规模体外药物扰动基因表达谱数据集比较,识别候选化合物。
- 在MPTP损伤猕猴模型中对候选化合物SB-0107及其氘代类似物进行药理学评价。
主要发现
- 不同剂量左旋多巴在小鼠纹状体中产生与抗帕金森作用和运动障碍相关的 distinct 基因表达特征。
- 通过基因表达特征比对识别出SB-0107,一种具有既往临床经验的蛋白激酶A II型正性变构调节剂。
- SB-0107在MPTP损伤猕猴模型中增强左旋多巴的获益并减少运动障碍。
- 氘代类似物(包括SB-0110)改善了药代动力学和药理效应。
临床怎么用
- 该化合物具有既往临床经验的安全性和氘代类似物改善的药代动力学特性,支持作为左旋多巴辅助治疗进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Maximizing clinical benefits of therapeutics while minimizing adverse effects is a central challenge in drug development. For Parkinson's disease (PD), l-3,4-dihydroxyphenylalanine (l-dopa) is the most effective treatment available, but chronic use is associated with periods of reduced efficacy (motor fluctuations) and the debilitating on-target side effect of l-dopa-induced dyskinesia. To disentangle the molecular mechanisms underlying l-dopa's antiparkinsonian effects versus its dyskinetic effects, we analyzed transcriptomic data from the striata of mice exposed to different l-dopa doses, identifying distinct gene expression signatures associated with l-dopa's effect on parkinsonian motor symptoms and dyskinesia. By comparing these gene expression signatures with a large dataset of in vitro gene expression profiles of drug perturbations, we identified SB-0107, a positive allosteric modulator of protein kinase A type II with previous clinical experience that boosts l-dopa's benefits while reducing dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaque model of PD. Deuterated analogs, including SB-0110, were developed that improved both pharmacokinetics and pharmacological effects. This dual effect, established safety profile of the parent compound, and improved properties of the deuterated analog support further development of this compound as an adjunct treatment to l-dopa therapy for PD.
引用
- Bordbar A, Bloem B, Lloyd C, et al. A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease. Sci Transl Med. 2026. PMID: 42455901. doi:10.1126/scitranslmed.aec7409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。